SUTRO BIOPHARMA, INC. Earnings Per Share, Basic and Diluted
SUTRO BIOPHARMA, INC. (STRO) reported Earnings Per Share, Basic and Diluted of -$0.84 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.84.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.66.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.84.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for the quarter ending 2019-12-31 was -$0.65.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.29.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for fiscal 2020 was -$0.99.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for fiscal 2019 was -$2.43.
- SUTRO BIOPHARMA, INC. earnings per share, basic and diluted for fiscal 2018 was -$6.13.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.84 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | -$2.29 10-K · filed 2022-02-28 | |||
| 2021-03-31 | -$0.66 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$0.99 10-K · filed 2022-02-28 | |||
| 2020-03-31 | -$0.84 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | -$0.65 10-K · filed 2021-03-18 | -$2.43 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$0.56 10-K · filed 2021-03-18 | -$1.16 derived: net income ÷ weighted average shares · filed 2019-11-08 | -$1.79 10-Q · filed 2019-11-08 | |
| 2019-06-30 | -$0.60 10-K · filed 2021-03-18 | -$1.22 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | -$0.62 10-K · filed 2021-03-18 | |||
| 2018-12-31 | -$0.07 10-K · filed 2020-03-16 | -$6.13 10-K · filed 2021-03-18 | ||
| 2018-09-30 | -$21.26 10-K · filed 2020-03-16 | -$45.41 derived: net income ÷ weighted average shares · filed 2019-11-08 | -$71.06 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$24.17 10-K · filed 2020-03-16 | -$49.90 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$25.76 10-K · filed 2020-03-16 | |||
| 2017-12-31 | -$33.51 10-K · filed 2019-04-01 | -$43.95 10-K · filed 2020-03-16 | ||
| 2017-09-30 | -$3.14 10-K · filed 2019-04-01 | -$9.77 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$4.07 10-K · filed 2019-04-01 | |||
| 2017-03-31 | -$2.55 10-K · filed 2019-04-01 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |